Innovative Immunotherapy Combo Tests IDO Inhibitor in Melanoma Trial – OncLive
|
Innovative Immunotherapy Combo Tests IDO Inhibitor in Melanoma Trial
OncLive Investigators are looking into a novel immunotherapy combination that pairs the first-in-class IDO1 inhibitor epacadostat (INCB024360) with the checkpoint blockade agent pembrolizumab (Keytruda) in patients with unresectable or metastatic melanoma. |
